Clinical Trial Update: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 [Phase 1]

View source ↗

Summary

A Phase 1 study of NPX267 in subjects with solid tumors expressing HHLA2/B7-H7 is currently suspended. Sponsor: NextPoint Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• NPX267 (NPX267)

Snippet

Sponsor: NextPoint Therapeutics, Inc. | Conditions: Metastatic Malignant Neoplasm | Phase 1 | Status: SUSPENDED